Iclaprim Clinical Trial Supplies Manufactured

By Uncategorized
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites. These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017. Graham Lumsden, CEO, stated: “This is a major milestone for Motif given the complexity and costs usually associated with the manufacture of clinical trial supplies in sufficient quantity for large Phase III trials.  We were able to utilise commercial-scale batches of the API (Active Pharmaceutical Ingredient) that we own as a result of our...
Read More